BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27825759)

  • 1. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
    Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
    Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
    Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
    Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
    Gupta B; Poudel BK; Regmi S; Pathak S; Ruttala HB; Gautam M; An GJ; Jeong JH; Choi HG; Yong CS; Kim JO
    Pharm Res; 2018 Mar; 35(5):96. PubMed ID: 29536182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
    Pang J; Xing H; Sun Y; Feng S; Wang S
    Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
    Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
    J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells.
    Bruinsmann FA; Buss JH; Souto GD; Schultze E; de Cristo Soares Alves A; Seixas FK; Collares TV; Pohlmann AR; Guterres SS
    AAPS PharmSciTech; 2020 Aug; 21(6):229. PubMed ID: 32778976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
    Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X
    Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib complexation with randomly methylated
    Erdoğar N; Akkın S; Varan G; Bilensoy E
    Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly-L-asparagine nanocapsules as anticancer drug delivery vehicles.
    Rivera-Rodríguez GR; Alonso MJ; Torres D
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):481-7. PubMed ID: 23954509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
    Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
    AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative.
    Lollo G; Hervella P; Calvo P; Avilés P; Guillén MJ; Garcia-Fuentes M; Alonso MJ; Torres D
    Int J Pharm; 2015 Apr; 483(1-2):212-9. PubMed ID: 25681727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
    Yin N; Yu H; Zhang X; Lv X
    Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
    Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
    Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo.
    Klippstein R; Wang JT; El-Gogary RI; Bai J; Mustafa F; Rubio N; Bansal S; Al-Jamal WT; Al-Jamal KT
    Small; 2015 Sep; 11(36):4704-22. PubMed ID: 26140363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
    Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel.
    Lollo G; Rivera-Rodriguez GR; Bejaud J; Montier T; Passirani C; Benoit JP; García-Fuentes M; Alonso MJ; Torres D
    Eur J Pharm Biopharm; 2014 May; 87(1):47-54. PubMed ID: 24530693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
    Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
    Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.